Allogene Therapeutics, Inc. Balance Sheet
ALLO|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
Allogene Therapeutics, Inc. had $416M in total assets and $293M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $51.7M | $75.2M | $83.2M | $84.5M | $173.3M |
| Current Assets | $257.7M | $303.4M | $459.1M | $469.7M | $471.3M |
| PP&E (Net) | $72.8M | $86.1M | $99.5M | $120.2M | $123.0M |
| Total Assets | $415.9M | $548.7M | $642.8M | $978.1M | $1.0B |
| Current Liabilities | $32.5M | $35.5M | $37.1M | $36.6M | $48.2M |
| Shareholders' Equity | $292.5M | $512.2M | $666.9M | $666.9M | $629.0M |